Humira ― for a long time the world’s top-selling drug, and still one of the biggest brands in the business – finally faced US biosimilar competition this year, with Amgen at the end of January launching the first of many adalimumab biosimilars approved by the US Food and Drug Administration. A multitude of other competitors are bringing further adalimumab biosimilars to the US market, as per the terms of their individual litigation settlements with originator AbbVie.

You can also download the PDF by clicking the button below

Related Resources

JUL 01, 2023

Floodgates Open for US Humira Biosimilars; Key TB Drug Can Move in India

Generics Bulletin previews the most notable and anticipated events for July 2023

MAR 01, 2023

Q2 2023 Pharma Outlook Report

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q2 2023.

DEC 01, 2022

In Vivo Outlook 2023

Outlook 2023 includes exclusive interviews and features on topics that reach across the life sciences.